Composite Probiotic Strains for Synergistic Colitis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating colitis, particularly ulcerative colitis, are limited, and there is a need for more effective probiotics that can synergistically address symptoms such as body weight loss, inflammatory factor imbalance, oxidative stress, and intestinal flora dysbiosis.
Innovation Solution
A composite probiotic formulation combining Pediococcus acidilactici PA53 strain (CGMCC No. 18798) and Lactobacillus helveticus LH76 strain (CGMCC No. 18796) is developed, which exhibits synergistic effects in alleviating colitis by improving gut microecology, enhancing local immunity, and increasing short-chain fatty acids, with a viable bacteria ratio of 1:5 to 5:1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-strain probiotics are used to treat colitis, then the treatment strategy is simple, but the therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines two probiotic strains (Pediococcus acidilactici PA53 and Lactobacillus helveticus LH76) into a composite formulation. The synergistic effect of these two strains significantly improves therapeutic efficacy for colitis compared to single-strain probiotics, while maintaining manageable formulation complexity through defined ratios (1:5 to 5:1) and standardized preparation methods.
2Reliability
If probiotic strains are compounded to enhance efficacy, then the therapeutic effect improves, but the formulation complexity increases
Solution Approach 1:
The patent optimizes the formulation by defining specific ratio ranges (1:5 to 5:1) for the two probiotic strains. This parameter optimization ensures synergistic therapeutic effects while maintaining formulation simplicity and manufacturability. The standardized ratio range balances efficacy enhancement with formulation complexity control.
3Adaptability or versatility
If more probiotic strains are added to address multiple symptoms, then the treatment coverage improves, but the safety and resistance risk may increase
Solution Approach 1:
The composite probiotic formulation addresses multiple colitis symptoms simultaneously including body weight loss, inflammatory factor imbalance, oxidative stress, and intestinal flora dysbiosis. The two selected strains work synergistically to provide broad-spectrum therapeutic coverage while maintaining safety profiles characteristic of probiotic organisms, avoiding the risks associated with antibiotic treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composite probiotic significantly reduces disease activity index, restores colon length, balances inflammatory factors, alleviates oxidative stress, and increases short-chain fatty acids, offering superior efficacy compared to single-strain interventions, with high safety and low resistance risk.
Implementation Method 1
probiotics can competitively inhibit pathogenic bacteria from colonizing the intestinal epithelium, thereby effectively reducing the damage of these pathogenic bacteria to the intestinal mucosa
Implementation Method 2
probiotics can improve gut microecology by increasing the number of beneficial bacteria while reducing the proportion of harmful bacteria, thereby alleviating dysbiosis of intestinal flora in patients with colitis
Implementation Method 3
probiotics can also stimulate the intestinal mucosal immune system, thereby enhancing local immunity and improving defensive capabilities against pathogens
Implementation Method 4
probiotics can also promote the proliferation and repair of intestinal mucosal cells, thereby reducing intestinal inflammatory symptoms in patients with colitis
Implementation Method 5
increasing the content of short-chain fatty acid in intestinal tracts
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Provided are a composite probiotic for preventing and treating colitis and use thereof. The composite probiotic for preventing and treating colitis is prepared from a Pediococcus acidilactici PA53 strain and a Lactobacillus helveticus LH76 strain. The two probiotics can cooperate with each other, exhibit mutual enhancement, and have synergistic effects on the prevention and treatment of colitis, specifically manifested in: relieving the body weight loss caused by colitis, reducing the disease activity index, and recovering the colon length; improving inflammatory factor imbalance and oxidative stress responses induced by colitis; and increasing the content of short-chain fatty acid in intestinal tracts. At equivalent total bacterial counts, compared with strain interventions lacking either bacterium, the compounding of the two bacteria has a significantly improved effect on the prevention and treatment of colitis.